Consolidation in the generics sector continued as Mylan NV picked up Sweden's Meda for $9.9bn, quickly answering analysts' questions about whether the company would seek further M&A during 2016.
The deal announcement was pushed out by the company along with strong full-year earnings that saw continued strength in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?